Shortening the duration of treatment for cervical tuberculous lymphadenitis
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The aim of the study was to determine the optimal duration of treatment for patients with tuberculous lymphadenitis. The Medline database was searched for relevant articles published between 1978-1997. Inclusion criteria were study populations of patients with predominantly cervical tuberculous lymphadenitis in whom the diagnosis had been confirmed bacteriologically and/or histologically, or was made probable by using clinical and laboratory markers. Treatment management had to include at least isoniazid, rifampicin and pyrazinamide and a follow-up of at least 12 months after the end of treatment. Patients with resistance to rifampicin and pyrazinamide and previous treatment for tuberculosis were excluded. The number of patients who relapsed after treatment was calculated. The study population in eight out of the 35 articles retrieved were suitable for analysis. Some concerned comparative studies. There were eight treatment schedules of 6 months' duration and three schedules of 9 months' duration. Treatment for 6 months resulted in a tuberculous lymphadenitis relapse rate of 13/422=3.3% (95% confidence interval: 1.7-5.5), with a mean follow-up of 31 months after completion of treatment. Treatment for 9 months resulted in a relapse rate of 3/112=2.7% (95% confidence interval: 0.6-7.8), with a mean follow-up of 20 months. Despite the limitations of the literature available, 6 months of therapy is probably sufficient for patients with tuberculous lymphadenitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 6-month recommendation is supported by studies that showed no difference between 6 and 9 months of treatment in cure rates (89%-94%) [45, 46] or relapse rates (3%) [47].”
From Current diagnosis and management of peripheral tuberculous lymphadenitis. (2011) · cites this paper as [47]
Citations
Cites
Bass, J. B., Farer, L. S., Hopewell, P. C., O'Brien, R., Jacobs, R. F., Ruben, F., Snider, D. E., & Thornton, G. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.5.8173779 · Cited by 1,193
Treatment for tuberculosis, guidelines for national programmes
Gyselen, E. A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90025-6 · Cited by 708
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998
Joint Tuberculosis Committee of the British Thoracic Society (1998) · Thorax · doi:10.1136/thx.53.7.536 · Cited by 527
Epidemiology of Extrapulmonary Tuberculosis
Mehta, J. B., Dutt, A., Harvill, L., & Mathews, K. M. (1991) · Chest · doi:10.1378/chest.99.5.1134 · Cited by 275 · cited 1×
“Lymph node tuberculosis, occurring predominantly in the cervical region, is the most common manifestation of extrapulmonary tuberculosis [1].”
BackgroundTreatment of Tuberculosis and Tuberculosis Infection in Adults and Children
Ad Hoc Committee of the Scientific Assembly on Microbiology, T. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.9 · Cited by 262
Six months versus nine months chemotherapy for tuberculosis of lymph nodes: Final results
Campbell, I. A., Ormerod, L. P., Friend, J. A. R., Jenkins, P. A., & Prescott, R. J. (1993) · Respiratory Medicine · doi:10.1016/s0954-6111(05)80265-3 · Cited by 87 · cited 7×
“Nodes were present after treatment in 143/423=34% of the patients [7, 8, 10, 11, 13].”
BackgroundResultInfluentialKumar, L., Dhand, R., SINGHI, P. D., RAO, K. L. N., & KATARIYA, S. (1990) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199011000-00004 · Cited by 72 · cited 2×
“4) [9]** 2H2R2Z2/4H2R2 15 100 100 24- 0/15 [9]** 2HRZ/4H2R2 12 1 100 100 24- 0/11 [10, 11] 2HRZ/4HR 66 6 2 6 1 77 98 24- 3/51 (5.”
BackgroundShort course chemotherapy for tuberculous lymphadenitis in children.
Jawahar, M. S., Sivasubramanian, S., Vijayan, V. K., Ramakrishnan, C. V., Paramasivan, C. N., Selvakumar, V, Paul, S., Tripathy, S. P., & Prabhakar, R. (1990) · BMJ · doi:10.1136/bmj.301.6748.359 · Cited by 64 · cited 7×
“Five patients relapsed during the first year [7, 8, 13] three patients relapsed later, and in eight patients there was no further information [7±12].”
BackgroundInfluentialYUEN, A., WONG, S., TAM, C., CHAN, S., WEI, W., & LAU, S. (1997) · Otolaryngology - Head and Neck Surgery · doi:10.1016/s0194-5998(97)70323-1 · Cited by 48 · cited 2×
“3) [12] 4S3H3R3Z3/5H3R3 64 13 3 1 # 73 98 21+ 1/47 (2.”
Mycobacterial lymphadenitis in Western Australia
Pang, S. C. (1992) · Tubercle and Lung Disease · doi:10.1016/0962-8479(92)90041-h · Cited by 34 · cited 3×
“The dose of anti-tuberculous drugs used varied and was not reported in one study [14].”
Background
Cited by
Diagnosis and Treatment of Extrapulmonary Tuberculosis
Lee, J. Y. (2015) · Tuberculosis and Respiratory Diseases · doi:10.4046/trd.2015.78.2.47 · Cited by 512
Current diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
“The 6-month recommendation is supported by studies that showed no difference between 6 and 9 months of treatment in cure rates (89%–94%) [45, 46] or relapse rates (3%) [47].”
BackgroundExtrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance
Gopalaswamy, R., Dusthackeer, A., Kannayan, S., & Subbian, S. (2021) · Journal of Respiration · doi:10.3390/jor1020015 · Cited by 242
A Nested Case–Control Study on Treatment-related Risk Factors for Early Relapse of Tuberculosis
Chang, K. C., Leung, C. C., Yew, W. W., Ho, S. C., & Tam, C. M. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-905oc · Cited by 137
Interventions for tuberculosis control and elimination.
Rieder, H. L., & Disease, L. (2002) · Cited by 162
Metadata
- Authors
- van Loenhout-Rooyackers, J., Laheij, R., Richter, C., & Verbeek, A.
- Affiliations
- Radboud University Nijmegen (NL)
- Rijnstate Hospital (NL)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2000-01-01
- Volume
- 15
- Issue
- 1
- Pages
- 192-195
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2145192125
- Cited by
- 62
- References
- 17
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 1 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculous lymphadenitis, cervical lymphadenitis, treatment duration, isoniazid, rifampicin, pyrazinamide, relapse rate, tuberculosis treatment
- MeSH terms
- Antitubercular Agents, Drug Administration Schedule, Drug Therapy, Combination, Follow-Up Studies, Humans, Isoniazid, Neck, Pyrazinamide, Rifampin, Tuberculosis, Lymph Node, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shortening the duration of treatment for cervical tuberculous lymphadenitis. https://app.cochat.ai/papers/10.1183/09031936.00.15119200
- The paper
- van Loenhout-Rooyackers, J., Laheij, R., Richter, C., & Verbeek, A. (2000). Shortening the duration of treatment for cervical tuberculous lymphadenitis. European Respiratory Journal. https://doi.org/10.1183/09031936.00.15119200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.